| Alexander Valley Healthcare | |
|
6 Tarman Dr Cloverdale CA 95425-3932 | |
| (707) 894-4229 | |
| Not Available |
| Full Name | Alexander Valley Healthcare |
|---|---|
| Speciality | Clinic/Center |
| Location | 6 Tarman Dr, Cloverdale, California |
| Authorized Official Name and Position | Patrick Richards (CONTROLLER) |
| Authorized Official Contact | 7076691780 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Alexander Valley Healthcare 106 E 1st St Cloverdale CA 95425-3746 Ph: (707) 669-1780 | Alexander Valley Healthcare 6 Tarman Dr Cloverdale CA 95425-3932 Ph: (707) 894-4229 |
| NPI Number | 1033534466 |
|---|---|
| Provider Enumeration Date | 02/21/2014 |
| Last Update Date | 06/20/2023 |
| Medicare PECOS PAC ID | 3274445465 |
|---|---|
| Medicare Enrollment ID | O20031105000381 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033534466 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 110000318 (California) | Primary |
| Provider Name | Jing Zhao |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1376621862 PECOS PAC ID: 3072571330 Enrollment ID: I20070502000525 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | James T Murphy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578544755 PECOS PAC ID: 9133209828 Enrollment ID: I20081002000604 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | Joann Rosenfeld |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215031588 PECOS PAC ID: 3779637236 Enrollment ID: I20090818000387 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | Amy Brom |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1861680845 PECOS PAC ID: 7113163205 Enrollment ID: I20130416000254 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | Gordana Potrebic |
|---|---|
| Provider Type | Practitioner - Psychologist Billing Independently |
| Provider Identifiers | NPI Number: 1699960666 PECOS PAC ID: 5092022509 Enrollment ID: I20150916001335 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | Elizabeth L Pile |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881058022 PECOS PAC ID: 6800181546 Enrollment ID: I20160819002132 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | Marianne L Rickards |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1306933585 PECOS PAC ID: 4789094228 Enrollment ID: I20201111002796 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
| Provider Name | Donghyun Kim |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1548614563 PECOS PAC ID: 6305130592 Enrollment ID: I20220719000500 |
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
News Archive
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
› Verified 7 days ago
Alexander Valley Healthcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6 Tarman Dr, Cloverdale, CA 95425 Phone: 707-894-4229 Fax: 707-894-2954 | |
Alexander Valley Healthcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6 Tarman Drive, Cloverdale, CA 95425 Phone: 707-894-4229 Fax: 707-894-2954 | |
Alexander Valley Healthcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 106 E 1st St, Cloverdale, CA 95425 Phone: 707-894-4229 Fax: 707-894-2954 | |
Alexander Valley Healthcare Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 100 W 3rd St, Cloverdale, CA 95425 Phone: 707-894-4229 | |
Cmhc Cloverdale Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 140 S Cloverdale Blvd, Cloverdale, CA 95425 Phone: 707-894-4715 |